Technology platforms for complex challenges
We believe the greatest innovations create value where patient needs, partner needs, and expertise intersect.
Patients are looking for treatments that not only offer optimal outcomes, but also that require less frequent dosing and reduce overall treatment burden. At the same time, pharmaceutical partners are seeking differentiated products, lifecycle extension opportunities, and efficient development pathways that create additional value from existing and future therapies.
Nanomi helps bring these objectives together through our long-acting injectable platforms, formulation expertise, and development capabilities.
How our platforms help partners
The best way to understand what is possible for your molecule is a conversation. Many opportunities only become clear once we look at your program together. Contact us at bd@nanomi.com to explore how our platforms can work for you.
Partners come to Nanomi with different objectives: exploring lifecycle extension opportunities, addressing formulation and stability challenges, developing differentiated products, or improving patient outcomes through optimized drug delivery with enhanced convenience. Behind each of these goals is a shared ambition to create better outcomes for patients while maximizing the value of innovative therapies.
Nanomi brings these goals together through long-acting injectable expertise, proprietary platform technologies, and integrated development and manufacturing capabilities. Whatever your starting point is, our platforms may help create value where patient needs, partner goals, and Nanomi’s expertise intersect.
Innovative platforms for better patient outcomes and partner value
Unlike conventional long-acting injectable technologies that produce variable particle sizes, our long-acting injectable platforms enable the production of medicines with uniform particle size, shape, and biological properties, leading to optimal treatment outcomes through improved medication delivery and increased patient convenience. This happens because our controlled particle sizes ensure steady drug concentration levels and can be used with smaller needles to reduce pain and discomfort. As a result, patients receive the optimal dose of medication, and experience enhanced convenience, which together may lead to greater compliance and potentially better treatment outcomes.
Our complementary platforms can be applied across a variety of chemical entities, including small molecules, peptides, and biologics.